거세저항성 전립선암 시장 규모, 점유율, 동향, 산업 분석 보고서 : 치료법별, 지역별 - 시장 예측(2025-2034년)

The castrate-resistant prostate cancer (CRPC) market size is expected to reach USD 29.79 billion by 2034, according to a new study by Polaris Market Research. The report "Castrate-Resistant Prostate Cancer Market Share, Size, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The castrate-resistant prostate cancer market growth is attributed to increasing incidence rates, especially among aging populations. Prostate cancer often progresses to a more advanced, treatment-resistant stage. Thus, the demand for effective therapies has grown, leading to advancements in targeted treatments and precision oncology. Key players such as Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; and Astellas Pharma, Inc. drive this market with leading products and continued innovation. The CRPC market size has expanded as major companies focus on novel therapies such as androgen receptor inhibitors, immunotherapies, and other targeted approaches. Such advancements have contributed to increased market share among companies offering comprehensive CRPC treatment options.

The castrate-resistant prostate cancer market trends indicate a shift toward personalized medicine and combination therapies that offer enhanced efficacy with fewer side effects. North America dominates the global market due to robust healthcare infrastructure, high awareness, and established medical research institutions. However, Asia Pacific is expected to witness the highest CAGR due to rising prostate cancer incidence, improved healthcare access, and regulatory support for new treatments. The castrate-resistant prostate cancer market (CRPC) market growth in these regions reflects a broader global trend of increasing investments in oncology research and treatment. Additionally, partnerships, and mergers and acquisitions are prevalent, as companies seek to expand their product pipelines and geographic reach, further fueling the castrate-resistant prostate cancer market expansion.

Castrate-Resistant Prostate Cancer Market Report Highlights

In terms of therapy, in 2024, the hormonal therapy segment accounted for the largest share of the castrate-resistant prostate cancer market due to its proven effectiveness in slowing disease progression by reducing androgen levels.

The immunotherapy segment is expected to witness the highest CAGR during the forecast period due to its ability to harness the body's immune system to specifically target and attack prostate cancer cells, offering a promising and less invasive treatment option.

In 2024, North America dominated the castrate-resistant prostate cancer market share due to its advanced healthcare infrastructure and high prevalence of prostate cancer.

The Asia Pacific market is expected to witness significant growth during the forecast period due to the growing awareness of advanced treatment options and supportive government initiatives in cancer care.

A few global key market players are Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; and Dendreon Corporation.

Polaris Market Research has segmented the castrate-resistant prostate cancer market report on the basis of therapy, and region:

By Therapy Outlook (Revenue, USD Billion; 2020-2034)

• Chemotherapy
• Hormonal Therapy
• Immunotherapy
• Radiotherapy

By Regional Outlook (Revenue, USD Billion; 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific
• Latin America
• Argentina
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Castrate-resistant Prostate Cancer Market Insights

• 4.1. Castrate-resistant Prostate Cancer Market - Market Snapshot
• 4.2. Castrate-resistant Prostate Cancer Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising Incidence of Prostate Cancer
    • 4.2.1.2. Growing Geriatric Population
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Limited Treatment Options for Late-stage Disease
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Castrate-resistant Prostate Cancer Market Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Castrate-resistant Prostate Cancer Market, by Therapy

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
• 5.3. Chemotherapy
  • 5.3.1. Global Castrate-resistant Prostate Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
• 5.4. Hormonal Therapy
  • 5.4.1. Global Castrate-resistant Prostate Cancer Market, by Hormonal Therapy, by Region, 2020-2034 (USD Billion)
• 5.5. Immunotherapy
  • 5.5.1. Global Castrate-resistant Prostate Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
• 5.6. Radiotherapy
  • 5.6.1. Global Castrate-resistant Prostate Cancer Market, by Radiotherapy, by Region, 2020-2034 (USD Billion)

6. Global Castrate-resistant Prostate Cancer Market, by Geography

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Castrate-resistant Prostate Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
• 6.3. Castrate-resistant Prostate Cancer Market - North America
  • 6.3.1. North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.3.2. Castrate-resistant Prostate Cancer Market - U.S.
    • 6.3.2.1. U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.3.3. Castrate-resistant Prostate Cancer Market - Canada
    • 6.3.3.1. Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
• 6.4. Castrate-resistant Prostate Cancer Market - Europe
  • 6.4.1. Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.2. Castrate-resistant Prostate Cancer Market - UK
    • 6.4.2.1. UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.3. Castrate-resistant Prostate Cancer Market - France
    • 6.4.3.1. France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.4. Castrate-resistant Prostate Cancer Market - Germany
    • 6.4.4.1. Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.5. Castrate-resistant Prostate Cancer Market - Italy
    • 6.4.5.1. Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.6. Castrate-resistant Prostate Cancer Market - Spain
    • 6.4.6.1. Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.7. Castrate-resistant Prostate Cancer Market - Netherlands
    • 6.4.7.1. Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.8. Castrate-resistant Prostate Cancer Market - Russia
    • 6.4.8.1. Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4.9. Castrate-resistant Prostate Cancer Market - Rest of Europe
    • 6.4.9.1. Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
• 6.5. Castrate-resistant Prostate Cancer Market - Asia Pacific
  • 6.5.1. Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.2. Castrate-resistant Prostate Cancer Market - China
    • 6.5.2.1. China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.3. Castrate-resistant Prostate Cancer Market - India
    • 6.5.3.1. India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.4. Castrate-resistant Prostate Cancer Market - Malaysia
    • 6.5.4.1. Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.5. Castrate-resistant Prostate Cancer Market - Japan
    • 6.5.5.1. Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.6. Castrate-resistant Prostate Cancer Market - Indonesia
    • 6.5.6.1. Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.7. Castrate-resistant Prostate Cancer Market - South Korea
    • 6.5.7.1. South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.8. Castrate-resistant Prostate Cancer Market - Australia
    • 6.5.8.1. Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5.9. Castrate-resistant Prostate Cancer Market - Rest of Asia Pacific
    • 6.5.9.1. Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
• 6.6. Castrate-resistant Prostate Cancer Market - Middle East & Africa
  • 6.6.1. Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6.2. Castrate-resistant Prostate Cancer Market - Saudi Arabia
    • 6.6.2.1. Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6.3. Castrate-resistant Prostate Cancer Market - UAE
    • 6.6.3.1. UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6.4. Castrate-resistant Prostate Cancer Market - Israel
    • 6.6.4.1. Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6.5. Castrate-resistant Prostate Cancer Market - South Africa
    • 6.6.5.1. South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6.6. Castrate-resistant Prostate Cancer Market - Rest of Middle East & Africa
    • 6.6.6.1. Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
• 6.7. Castrate-resistant Prostate Cancer Market - Latin America
  • 6.7.1. Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7.2. Castrate-resistant Prostate Cancer Market - Mexico
    • 6.7.2.1. Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7.3. Castrate-resistant Prostate Cancer Market - Brazil
    • 6.7.3.1. Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7.4. Castrate-resistant Prostate Cancer Market - Argentina
    • 6.7.4.1. Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7.5. Castrate-resistant Prostate Cancer Market - Rest of Latin America
    • 6.7.5.1. Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

7. Competitive Landscape

• 7.1. Expansion and Acquisition Analysis
  • 7.1.1. Expansion
  • 7.1.2. Acquisitions
• 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

• 8.1. Sanofi S.A.
  • 8.1.1. Company Overview
  • 8.1.2. Financial Performance
  • 8.1.3. Product Benchmarking
  • 8.1.4. Recent Development
• 8.2. Johnson & Johnson
  • 8.2.1. Company Overview
  • 8.2.2. Financial Performance
  • 8.2.3. Product Benchmarking
  • 8.2.4. Recent Development
• 8.3. Pfizer, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Financial Performance
  • 8.3.3. Product Benchmarking
  • 8.3.4. Recent Development
• 8.4. Bayer AG
  • 8.4.1. Company Overview
  • 8.4.2. Financial Performance
  • 8.4.3. Product Benchmarking
  • 8.4.4. Recent Development
• 8.5. Abbott Laboratories
  • 8.5.1. Company Overview
  • 8.5.2. Financial Performance
  • 8.5.3. Product Benchmarking
  • 8.5.4. Recent Development
• 8.6. GlaxoSmithKline PLC
  • 8.6.1. Company Overview
  • 8.6.2. Financial Performance
  • 8.6.3. Product Benchmarking
  • 8.6.4. Recent Development
• 8.7. Northwest Biotherapeutics, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Financial Performance
  • 8.7.3. Product Benchmarking
  • 8.7.4. Recent Development
• 8.8. Active Biotech AB
  • 8.8.1. Company Overview
  • 8.8.2. Financial Performance
  • 8.8.3. Product Benchmarking
  • 8.8.4. Recent Development
• 8.9. Astellas Pharma, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Financial Performance
  • 8.9.3. Product Benchmarking
  • 8.9.4. Recent Development
• 8.10. Dendreon Corporation
  • 8.10.1. Company Overview
  • 8.10.2. Financial Performance
  • 8.10.3. Product Benchmarking
  • 8.10.4. Recent Development